18:06 , Jun 29, 2018 |  BC Week In Review  |  Company News

Renal plays Akebia, Keryx merging

Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined company with one chronic kidney disease compound on the market and another in Phase III testing. Keryx shareholders...
22:09 , Jun 28, 2018 |  BC Extra  |  Company News

Renal plays Akebia, Keryx merging

Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined company with one chronic kidney disease compound on the market and another in Phase III testing. The...
00:06 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

FDA approves Keryx's Auryxia for non-dialysis-dependent CKD

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) said FDA approved an sNDA for Auryxia ferric citrate (Fexeric - EU, Riona - Japan, KRX-0502, JTT-751) to treat iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease (CKD). The...
21:35 , Nov 7, 2017 |  BC Extra  |  Financial News

Keryx sags after withdrawing guidance

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) fell $1.08 (17%) to $5.15 Tuesday after it reported 3Q17 earnings and withdrew its 2017 guidance. The company reported revenues of $15 million for the quarter, falling short of the $18...
12:50 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

Auryxia regulatory update

FDA accepted for review an sNDA from Keryx for Auryxia ferric citrate to treat iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease (CKD). The PDUFA date is Nov. 6. The oral ferric iron-based...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Keryx sales and marketing update

Keryx said it expects an “imminent” interruption in the supply of Auryxia ferric citrate that will disrupt patient access to the drug. The company attributed the interruption to a “production-related issue” as its contract...
07:00 , Aug 1, 2016 |  BC Extra  |  Company News

Keryx expects Auryxia supply interruption

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) sank $2.64 (36%) to $4.72 on Monday after it said it expects an "imminent" interruption in the supply of Auryxia ferric citrate that will disrupt patient access to the drug. Keryx,...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

Auryxia: Phase III data

Top-line data from a double-blind, U.S. Phase III trial in 234 stage 3-5 non-dialysis-dependent CKD patients who did not adequately respond to or tolerate current oral iron therapies showed that oral Auryxia met the primary...
01:31 , Mar 30, 2016 |  BC Extra  |  Clinical News

Keryx's Auryxia meets in Phase III anemia study

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) rose $0.39 to $4.94 on Tuesday after its Auryxia ferric citrate met the primary endpoint in a Phase III trial to treat iron deficiency anemia in adults with non-dialysis dependent chronic...
08:00 , Feb 29, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg2/26 clsAchillion Pharmaceuticals Inc. (NASDAQ:ACHN)BairdBrian SkorneyUpgradeOutperform (from neutral)10%$7.35 Skorney upgraded and maintained his $10 target ahead of HCV data from a Phase IIa trial of Achillion's odalasvir plus...